# Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency

> **NCT00355264** · PHASE2 · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 12 (actual)

## Conditions studied

- Tetrahydrobiopterin Deficiencies
- Hyperphenylalaninemia, Non-Phenylketonuric

## Interventions

- **DRUG:** Phenoptin

## Key facts

- **NCT ID:** NCT00355264
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00355264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00355264, "Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00355264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*